Cayman Chemical 7-acetyl PaclItaxel 10mg
An inhibitor of native (IC50 0.37 nM) and mutant Bcr-Abl inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 2 nM) as well as Bcr-AblQ252H Bcr-AblY253F Bcr-AblM351T and Bcr-AblH396P mutants (IC50s 0.44 0.3 0.3 and 0.34 nM respectively) selective for Bcr-Abl and these mutants over the insulin receptor IGF-1R Aurora A kinase and Cdk2/cyclin E but does inhibit c-Src VEGFR2 FGFR1 and PDGFRa (IC50s 5.4 1.5 2.2 and 1.1 nM respectively) inhibits proliferation of Ba/F3 cells expressing native (IC50 0.5 nM) or mutant Bcr-Abl (IC50s 0.5-36 nM) reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model at 10-30 mg/kg